{"id":"https://openalex.org/W4301222764","doi":null,"title":"Topiglan MacroChem.","display_name":"Topiglan MacroChem.","publication_year":2002,"publication_date":"2002-04-01","ids":{"openalex":"https://openalex.org/W4301222764","pmid":"https://pubmed.ncbi.nlm.nih.gov/12090731"},"language":"en","primary_location":{"id":"pmid:12090731","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12090731","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113673854","display_name":"Chris G. McMahon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210107111","display_name":"Australian Centre for Sexual Health","ror":"https://ror.org/00zz54311","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210107111"]}],"countries":["AU"],"is_corresponding":true,"raw_author_name":"Chris G McMahon","raw_affiliation_strings":["Australian Center for Sexual Health, St Luke's Hospital Complex, Sydney. cmcmahon@mail.usyd.edu.au"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Australian Center for Sexual Health, St Luke's Hospital Complex, Sydney. cmcmahon@mail.usyd.edu.au","institution_ids":["https://openalex.org/I4210107111"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5113673854"],"corresponding_institution_ids":["https://openalex.org/I4210107111"],"apc_list":null,"apc_paid":null,"fwci":0.3656,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.60581378,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"3","issue":"4","first_page":"602","last_page":"6"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10459","display_name":"Sexual function and dysfunction studies","score":0.4657999873161316,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10459","display_name":"Sexual function and dysfunction studies","score":0.4657999873161316,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10704","display_name":"Advancements in Transdermal Drug Delivery","score":0.459199994802475,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.029100000858306885,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/prostaglandin-e1","display_name":"prostaglandin E1","score":0.9940000176429749},{"id":"https://openalex.org/keywords/erectile-dysfunction","display_name":"erectile dysfunction","score":0.7590000033378601},{"id":"https://openalex.org/keywords/topical-gel","display_name":"topical gel","score":0.949999988079071},{"id":"https://openalex.org/keywords/transdermal-drug-delivery","display_name":"transdermal drug delivery","score":0.8130000233650208},{"id":"https://openalex.org/keywords/sepa","display_name":"SEPA","score":0.7929999828338623},{"id":"https://openalex.org/keywords/new-drug-application","display_name":"new drug applications","score":0.824999988079071},{"id":"https://openalex.org/keywords/patent-claims","display_name":"patent claims","score":0.4790000021457672},{"id":"https://openalex.org/keywords/drug-development","display_name":"drug development","score":0.35899999737739563}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5633214116096497},{"id":"https://openalex.org/C2779913896","wikidata":"https://www.wikidata.org/wiki/Q7063001","display_name":"Notice","level":2,"score":0.42128652334213257},{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.2090357542037964},{"id":"https://openalex.org/C199539241","wikidata":"https://www.wikidata.org/wiki/Q7748","display_name":"Law","level":1,"score":0.1217317283153534}],"mesh":[{"descriptor_ui":"D000277","descriptor_name":"Adjuvants, Pharmaceutic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000279","descriptor_name":"Administration, Cutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000527","descriptor_name":"Alprostadil","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000527","descriptor_name":"Alprostadil","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000527","descriptor_name":"Alprostadil","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005782","descriptor_name":"Gels","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007172","descriptor_name":"Erectile Dysfunction","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014665","descriptor_name":"Vasodilator Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014665","descriptor_name":"Vasodilator Agents","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D014665","descriptor_name":"Vasodilator Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true}],"locations_count":1,"locations":[{"id":"pmid:12090731","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12090731","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2317533096","https://openalex.org/W2056521762","https://openalex.org/W2019994695","https://openalex.org/W2461574203","https://openalex.org/W1493360455","https://openalex.org/W845393316","https://openalex.org/W2038803382","https://openalex.org/W3093768488","https://openalex.org/W778862180","https://openalex.org/W3088008009"],"abstract_inverted_index":{"MacroChem":[0,42,72,217],"is":[1,131],"developing":[2],"Topiglan,":[3],"a":[4,82,113,179],"topical":[5],"gel":[6],"containing":[7],"prostaglandin":[8],"E1":[9],"(PGE1":[10],"or":[11,119],"alprostadil)":[12],"and":[13,88,211,228,231],"its":[14],"patented":[15,125],"through-the-skin":[16],"absorption":[17,133],"enhancer":[18,134],"excipient":[19],"(SEPA),":[20],"for":[21,48,135],"the":[22,58,107,140,145,151,159,167,173,233],"potential":[23,114,141],"treatment":[24],"of":[25,110,147,155,161,169,182,184],"erectile":[26],"dysfunction.":[27],"By":[28,39],"September":[29],"2000,":[30,41,216],"it":[31],"was":[32,196],"in":[33,50,68,116,129,190,198,208,222,225],"phase":[34,76],"III":[35,77],"clinical":[36],"trials":[37],"[382682].":[38],"October":[40],"expected":[43],"to":[44,142,158,172],"file":[45],"an":[46,132],"NDA":[47],"Topiglan":[49,130,189],"late":[51,117],"2002":[52],"[387433].":[53],"In":[54,214],"January":[55],"2002,":[56,111],"at":[57],"JP":[59],"Morgan":[60],"Hambrecht":[61],"&":[62],"Quist":[63],"20th":[64],"Annual":[65],"Healthcare":[66],"Conference":[67],"San":[69],"Francisco,":[70],"CA,":[71],"stated":[73],"that":[74,84,97,138],"further":[75,219],"studies":[78,102],"were":[79],"planned,":[80],"including":[81],"reformulation":[83],"could":[85],"reduce":[86],"initation":[87],"increase":[89,144],"dosage,":[90],"as":[91,93],"well":[92],"providing":[94],"new":[95],"packaging":[96],"improves":[98],"dose":[99],"consistency":[100],"These":[101],"should":[103],"be":[104],"underway":[105],"by":[106],"third":[108],"quarter":[109],"with":[112,232],"launch":[115],"2003":[118],"early":[120],"2004":[121],"[436390].":[122],"The":[123,153,176,193],"company's":[124],"SEPA":[126,156,174],"technology":[127],"used":[128],"transdermal":[136],"delivery":[137],"has":[139],"effectively":[143],"passage":[146],"therapeutic":[148],"agents":[149],"through":[150],"skin.":[152],"application":[154],"alone":[157],"skin":[160],"carcinogenic-sensitive":[162],"rats":[163],"did":[164],"not":[165],"cause":[166],"development":[168],"tumors":[170],"attributable":[171],"[357621].":[175],"company":[177],"received":[178],"US":[180],"notice":[181],"allowance":[183],"all":[185],"patent":[186,194,204,220],"claims":[187],"covering":[188],"February":[191,215],"1999.":[192],"(US-05942545)":[195],"issued":[197],"August":[199],"1999":[200],"[316028],":[201],"[337720].":[202,213],"Further":[203],"applications":[205,221],"are":[206],"pending":[207],"Canada,":[209],"Europe":[210],"Japan":[212],"filed":[218],"13":[223],"countries":[224],"Europe,":[226],"Asia":[227],"Latin":[229],"America":[230],"EPO":[234],"[355947].":[235]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2022-10-05T00:00:00"}